2 completed, 2 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow ARQ 197: new trials by email Literature Review of ARQ 197 trials Research Report on ARQ 197
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) ARQ197, Placebo - Liver Cancer | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 386 | 2014-01-01 | 2017-10-09 |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy Tivantinib, Placebo - Hepatocellular Carcinoma | Phase 3 | Completed | Daiichi Sankyo | 383 | 2012-12-27 | 2021-04-06 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib ARQ 197 and Erlotinib, Placebo and Erlotinib - Non-small-cell Lung Cancer | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 2011-07-01 | 2016-12-07 | |
| Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Tivantinib, Placebo, Erlotinib - Non Squamous, Non-small-cell Lung Cancer | Phase 3 | Terminated | Daiichi Sankyo | 1048 | 2011-01-11 | 2021-04-06 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Liver Neoplasms (1)
Daiichi Sankyo (2) · Kyowa Kirin Co., Ltd. (2)
Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · Spain (2) · Sweden (2) · United States (2) · Chile (1)
PMID 22440336, PMID 26153496, PMID 26169611, PMID 29625879, PMID 32716114